HD204 + carboplatin + paclitaxel

HD204 + carboplatin + paclitaxel is a combination regimen being developed and clinically investigated for oncology indications, typically advanced solid tumors. **HD204** is a proposed biosimilar to bevacizumab (EU-licensed Avastin), a recombinant humanized monoclonal antibody that inhibits angiogenesis by targeting vascular endothelial growth factor A (VEGF-A). **Carboplatin** is a platinum-based chemotherapeutic agent that causes DNA crosslinking, leading to apoptosis, while **paclitaxel** is a taxane that stabilizes microtubules and inhibits cell division. The combination is being studied to demonstrate equivalent efficacy and safety relative to reference bevacizumab (Avastin) plus carboplatin and paclitaxel, primarily in diseases such as non-small cell lung cancer.